BI
MRNA icon

Binnacle Investments’s Moderna MRNA Stock Holding History

Binnacle Investments’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$103 Buy
+4
New +$112 ﹤0.01% 925

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Binnacle Investments's MRNA Position: Q3 2025 in Review

Binnacle Investments opened a new position in Moderna (MRNA) in Q3 2025: 4 shares worth $103. The stake represents ﹤0.01% of the portfolio and ranks #925 among its holdings.

643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Binnacle Investments held 4 shares of Moderna worth $103 as of Q3 2025.
  • Moderna was a new Binnacle Investments position in Q3 2025.
  • Moderna made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #925 holding.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.